1. Prophylactic effect of cutaneous leishmaniasis against COVID-19: a case-control field assessment
- Author
-
Iraj Sharifi, Ehsan Salarkia, Maryam Barghi, Ahmad Khosravi, Amireh Heshmatkhah, Tabandeh Khaleghi, Amirhossein Tahmouresi, Ali Karamoozian, Mehdi Borhani Zarandi, Mehdi Bamorovat, Abdollah Jafarzadeh, Fatemeh Sharifi, Mohammad Reza Aflatoonian, and Maryam Nooshadokht
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Incidence (epidemiology) ,Field assessment ,Retrospective cohort study ,General Medicine ,Disease ,medicine.disease ,Infectious Diseases ,Cutaneous leishmaniasis ,Internal medicine ,medicine ,Coinfection ,business - Abstract
INTRODUCTION: We assessed the possible relationship between the COVID-19 with laboratory-confirmed CL-registered cases with a history of scar compared with healthy volunteer participants. METHODS: This case-control retrospective study was conducted in southeastern Iran with a high anthroponotic cutaneous leishmaniasis (ACL) burden. RESULTS: Overall, n=1,010 cases of CL consisting of n=479 male and n=531 female were analyzed for probable infection with SARS-CoV-2. Altogether, in the case group, two men and one woman (0.3%) were afflicted with a mild form of COVID-19 disease, and none of them were hospitalized or died. In contrast, out of n=2,020 healthy participants, n=57 (2.9%) contracted laboratory-confirmed COVID-19, including mild (66.7%), hospitalized (26.3%) and critical and death (3.5%, each). There was a strong negative association between CL infection and COVID-19. The burden of COVID-19 in CL-cured participants significantly reduced the morbidity (OR=0.12, CI: 0.03 - 0.30 and P
- Published
- 2022
- Full Text
- View/download PDF